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Background: Depression is a mental disorder characterized by a pervasive low mood and loss of pleasure or
interest in usual activities, and often results in cognitive dysfunction. The disturbance of cognitive processes
associated with depression, especially the impairment of learning and memory, exacerbates illness and increases
recurrence of depression. XingPiJieYu (XPJY) is one of the most widely clinical formulas of traditional Chinese
medicine (TCM) and can improve the symptoms of depression, including learning and memory. However, its
regulatory effects haven’t been comprehensively studied so far. Recently, some animal tests have indicated that the
cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-cAMP response element-binding protein (CREB)-
brain derived neurotrophic factor (BDNF) signaling pathway in hippocampus is closely related to depression and
the pathogenesis of cognitive function impairments. The present study was performed to investigate the effect and
mechanism of XPJY on depression and learning and memory in animal model.
Materials: The rat model of depression was established by chronic unpredictable stress (CUS) for 21 days. The rats
were randomly divided into six groups: control group, CUS group, CUS + XPJY (1.4 g/kg, 0.7 g/kg and 0.35 g/kg)
groups, and CUS + sertraline (10 mg/kg) group. The sucrose preference, open field exploration and Morris water
maze (MWM) were tested. The expression of cAMP, CREB, PKA and BDNF protein in hippocampus was examined
with Elisa and Western Blot. The mRNA level of CREB and BDNF in hippocampus was measured with PCR.
Results: The results demonstrated that rats subjected to CUS exhibited decreases in sucrose preference, total
ambulation, percentage of central ambulation, rearing in the open field test and spatial performance in the MWM.
CUS reduced the expression of cAMP, PKA, CREB and BDNF in hippocampus of model rats. These effects could be
reversed by XPJY.
Conclusion: The results indicated that XPJY can improve depression and related learning and memory and the
effect of XPJY is partly exerted through the cAMP-PKA-CREB-BDNF signaling pathway.
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Fig 1 The HPLC Chromatogram of XPJY
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Depression is a mental disorder characterized by a per-
vasive low mood and loss of pleasure or interest in usual
activities [1] and is the most common psychiatric illness
that involves the disturbance of mood, with 10 to 20%
lifetime prevalence [2]. The patients also demonstrate
sleeplessness and suicidal tendencies, decreased food-
intake and body-weight [3, 4], and more importantly al-
ways suffer from obvious cognitive function impair-
ments, such as delayed thinking correlation, reduced
computational capability, learning and memory impair-
ment, and reduction in attention, comprehension and
judgment [5–7]. Learning and memory impairment is
one of the important residual symptoms, which has a
strong impact on function of patients both at home and
workplace. On the other hand, it is becoming increas-
ingly clear that the disturbance of cognitive processes,
especially the impairment of learning and memory, plays
an important role in the development and complete
recurrence of depression [8, 9]. First of all, late-life de-
pression is a risk factor for cognitive decline [10]. Fur-
thermore, cognitive impairment is one of the typical
features of recurrent depressive disorder (rDD), predom-
inantly connected with episodic memory processes and
the frontal functions (working memory) [11–13]. Cogni-
tive impairment, linked with the earlier onset of depres-
sive symptoms and episode prolongation, may in return
lead to an ineffective antidepressant therapy and impede
full recovery [14]. So it is the demand of reality and also
an important task not to be avoided by mechanism
research.
At present, depression is commonly treated with
monoamine-based antidepressants such as selective
serotonin reuptake inhibitors (SSRI). However, about 1/3
of depressive patients are not responsive to conventional
antidepressants [15], and these drugs is associated with a
delay in symptom remission [16], severe side effects [17]
and unsatisfactory outcome in cognition. Therefore, the
treatment of depression is still a big problem and re-
quires more effective approaches.
Traditional Chinese Medicine (TCM) has a long his-
tory in preventing and treating depression in Asia and is
receiving more and more attention [18–22]. XPJY is a
common prescription in clinical practices and shows
relatively satisfactory therapeutic effect in improving de-
pression and learning and memory level. Previous stud-
ies have shown that XPJY could improve behaviour and
antidepression in chronic unpredictable stress model of
depression in rats, which was as good as sertraline, and
it also could reverse serum 5-HT and corticosterone
from depression rats. Another study found that XPJY
has the better effect on improving learning and memory
ability in depression rats than sertraline, which might he
related to reduce the inflammatory factors level, such asIL-1β, IL-6 and TNF-α, in serum and hippocampus. Re-
cently, some animal tests have indicated that the cyclic
adenosine monophosphate (cAMP)-protein kinase A
(PKA)-cAMP response element-binding protein (CREB)-
brain derived neurotrophic factor (BDNF) signaling
pathway in hippocampus is closely related to depression
and the pathogenesis of cognitive function impairments
[23–26]. However, the molecular mechanisms remain
unclear and require verification in animals. A further
study should be done this time. XPJY was composed of
the following dried raw materials: acori tatarinowii rhi-
zoma (Shi-Chang-pu), American ginseng (Xi-Yang-shen),
radix curcumae (Yu-Jin) and prepared rehmannia root
(Shoo-Di-huang). All of these were produced in accord-
ance with the China Pharmacopoeia standard of quality
control.
In the present study, we investigated the effects of
XPJY on rats with depression established by chronic un-
predictable stress and on the expression of cAMP-PKA-
CREB-BDNF signal pathway.
Methods
Preparation and compositional analysis of XPJY
XPJY was composed of the following granule, which
were derived from dried raw materials, including acori
tatarinowii rhizoma (Shi-Chang-pu), American ginseng
(Xi-Yang-shen), radix curcumae (Yu-Jin) and prepared
rehmannia root (Shoo-Di-huang), in weight ratio of
0.5:1.2:2:3. All granules were bought from medicinal Ma-
terials Company of Beijing KangRenTang Company
(Beijing, China), and analyzed for composition by high
performance liquid chromatography (HPLC). The test
solution was prepared by dissolving XPJY in methanol,
and analyzed on an Agilent 1200 HPLC system with an
C18 analytical column (250 × 4.6 mm, 5 μm). The mo-
bile phase was consisted of water and acetonitrile in gra-
dient elution. For quality control, the ginsenosides Rg1,
Re, Rb1 and acteoside were used as standard constitu-
ents. All the standards were purchased from National
Institutes for Food and Drug Control (Beijing, China).
As shown in Fig. 1, four bioactive compounds including
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exhibited high stability in XPJY by HPLC.
Animals and grouping
Adult male Sprague–Dawley rats (200–220 g) provided
by Beijing Academy of Military Medical Sciences
Laboratory Animal Centre were individually kept on a
12:12 h light/dark cycle in home cages with food and
water available ad libitum except as described in stress.
The experiment was approved by the Animal Ethic
Committee of the university. Sixty rats (10 rats in each
group) were randomly divided into six groups: control
group receiving once-daily oral gavage (PO.) administra-
tion of distilled water for 21 days, CUS group receiving
CUS and once-daily PO. administration of distilled water
for 21 days, CUS + sertraline group receiving CUS and
once-daily Po. sertraline at 10 mg/kg (Pfizer Inc., USA)
for 21 days, CUS and XPJY groups receiving CUS and
once-daily PO. XPJY at 0.35, 0.7 and 1.4 g/kg, respect-
ively, for 21 days. The sertraline diluted in distilled water
and XPJY were orally given 1 h before CUS exposure.
The dosage “0.7 g/kg” has been calculated based mainly
on the dosages of humans and animals. Then the double
dosage was considered as one group, half dosage as
another, hereby it works out that dose of XPJY is made
as three groups: 0.35, 0.7 and 1.4 g/kg.
Animal model preparation
The CUS procedure was modified from the procedures
used by Heine et al. [27]. Briefly, rats were exposed to
different stressors daily for 21 days as follows: day1, cold
immobilization for 1 h at 4 °C, forced swim for 30 min
at 25 °C; day 2, immobilization for 1 h, crowding for
23 h; day 3, forced cold swim stress for 5 min at 10 °C,
isolation for 23 h; day 4, immobilization for 1 h, vibra-
tion for 1 h; day 5, forced swim stress for 30 min at 25 °
C, cold immobilization for 1 h at 4 °C; day 6, forced cold
swim stress for 5 min at 10 °C, crowding for 23 h; day 7,
vibration for 1 h, isolation for 23 h. This schedule was
repeated twice for a total of 21 days. Prior to the study,
certain criteria were set for excluding animal on weight
loss, or the possible occurrence of wounds. Rats were ac-
climated to 3 min of handling once a day for 7 consecu-
tive days before being used in experiment and were
weighed on the 1st and 21th day of handling.
Sucrose preference test
Sucrose preference test was used to define anhedonia as
a reduction in sucrose intake and sucrose preference.
The sucrose preference test consisted of firstly removal
of the food and water from the cage for a period of 20 h.
Then water and 1% sucrose were placed back to the cage
and animals were allowed to consume the fluids freely
for a period of 1 h. The preference test was performedtwice, separated by at least 5 days to calculate the mean
for baseline. Then the preference test was conducted fol-
lowing the 21 days CUS period. On the last stress day, rats
were deprived of water and food for 20 h and from the
next day were given 1 h sucrose preference test (24 h after
the last drug treatment). Sucrose and water consumption
(ml) was measured and the sucrose preference was calcu-
lated as the sucrose preference (%) = sucrose consump-
tion/(sucrose consumption + water consumption).
Open field exploratory behavior test
Open field test was used to study the exploratory and
anxiety behaviors of rats and was performed after the
sucrose preference test. The rat was placed in the central
square and observed for 5 min by a video camera and
taped for further analysis. Motility was scored when the
rat crossed a sector border with both hind-limbs. The
following behaviors were scored by an observer who was
blind to the drug treatment: central ambulation, number
of central squares crossed; total ambulation, the overall
number of peripheral and central square crossed; rear-
ing, number of times the animal stood on its hind limbs;
grooming, number of times the animal made these re-
sponses viz. grooming of the face, licking/cleaning and
scratching the various parts of the body; immobility
period, the time spent immobile. Anxiety-related behavior
was measured by the percentage of central ambulation
and calculated as the percentage of central ambulation
(%) = central ambulation/total ambulation. Between tests,
the apparatus was cleaned with 5% alcohol.
Morris water maze test
After the final stress stimulation, the Morris water maze
(MWM) was used to determine the spatial learning and
memory of the rats. The behavior of the animal was
monitored with a video camera mounted in the ceiling
above the centre of the pool. For oriented navigation
test, the rats were trained for 120 s per trial and 4 trials
per day starting at four different positions with 30 min
intervals for 4 consecutive days as acquisition trials.
Each trial began with the rat in the pool facing the side-
walls. When the rat escaped onto the platform, the rat
was allowed to stay on the platform for 30 s before being
returned to home cage. If the rat failed to escape within
120 s, it was guided to the platform by the experimenter
and allowed to stay for 15 s. Each rat was trained once
in the morning and once in the afternoon, and the time
it took to find the platform (the latency period) was re-
corded. If the rats could not find the platform within
120 s, they were taken out the water and the time was
recorded as 120 s. For the spatial exploration test, the
hidden platform was removed on day 5, and memory re-
trieval was examined by a probe trial that lasted for
120 s. The escape latency in the acquisition trials, the
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spent in the target quadrant in the probe test were re-
corded by a computerised video tracking system.
Measurement of the expression level of cAMP level
After the last behavior test, hippocampus was taken out
and the cAMP content was evaluated using EliteTM
cAMP ELISA Assay Kit (eEnzyme, Montgomery Village,
MD, USA). Extracted supernatants in each sample were
loaded into EliteTM cAMP ELISA Assay Kit plates and
each procedure was performed according to the manu-
facturer’s instructions. After color development, the ab-
sorbance was measured at Ex/Em = 540/590 nm with
fluorescence reader (Bio-Rad, CA, USA).
Measurement of PKA, CREB, BDNF protein expressions by
western bolt
After the last behavior test, rats were sacrificed. Then
the hippocampus was dissected, put into chilled tubes
treated with an enzyme inhibitor and homogenized for
Western blot analysis as previously reported [27], using
primary antibodies for PKA, CREB and BDNF (1:2000,
Santa Cruz Biotechnology) and β-actin (1:10000, Santa
Cruz Biotechnology) followed by secondary antibodies
conjugated with horseradish peroxidase (HRP, 1:5000,
Bio-Rad). Immunoblots were visualized on X-ray film by
chemiluminescence reaction (Pierce), and image analysis
was performed on optical density calibrated images by
AlphaEase Stand Alone software (Alpha Innotech). All
experiments were performed 3 times.
Evaluation of mRNA expression levels of CREB and BDNF
by polymerase chain reaction (PCR)
Total RNA from the hippocampus was isolated with RNA-
Sure® Mini Kit according to the manufacturer’s protocol.
The concentration of extracted RNA was calculated from
the absorbance at 260 nm and the quality of RNA was
assessed by absorbance at 260 and 280 nm, with an accept-
able ratio of A260 to A280 ranging from 1.9 to 2.1. Total
RNA (1.5 mg) was transcribed using a high capacity cDNA
reverse transcription kit (The Maxima® First Strand cDNA
Synthesis Kit) according to the manufacturer’s protocol.
Real-time quantitative polymerase chain reaction (qPCR)
analysis was performed with a Maxima® SYBR Green qPCR
Master Mix (2X), using the StepOnePlusTM real-time PCR
system (Applied Bio systems, Inc., Foster City, CA). The
details of all oligonucleotide primer sequences are listed in
Table 1. The PCR reaction system was denaturation at 95 °
C for 15 min followed by 40 cycles of 94 °C for 15 s, 55 °C
for 30 s and 72 °C 45 s, with final extension at 72 °C for
10 min. Sequence Detection System Software (Version 1.0,
Applied Bio systems, Inc., Foster City, CA) was used for
data analysis. The relative expression of BDNF and CREB
mRNAs was normalized to the amount of GAPDH.Statistical analysis
The data were expressed as mean ± S.E.M and analyzed
by one-way ANOVA followed by Dunnet’s multiple




At the 1st day of the CUS period, rats from different
groups showed no significant difference in body
weight (p > 0.05). However, significant difference was
observed among groups following 21 days of CUS as
shown in Table 2 (p < 0.01). The CUS significantly at-
tenuated the gain of body weight when compared to
control group (p < 0.01). Treatment with XPJY at 0.7
and 1.4 g/kg significantly prevented the inhibition of
body weight gain induced by CUS (p < 0.01); however,
0.35 g/kg XPJY had no effect on the body weight gain
induced by CUS (p > 0.05). In addition, 10 mg/kg ser-
traline also prevented the effect of CUS on body
weight gain at day 21 of treatment (p < 0.01; Table 2).
Sucrose preference tests
Before the CUS period, rats from different groups
showed no significant difference in sucrose preference at
day 1. The sucrose preference was significantly reduced
in the CUS group relative to the control group after ex-
posure to CUS for 21 days (p < 0.01). Chronic treatment
with XPJY at 1.4 g/kg and sertraline at 10 mg/kg signifi-
cantly suppressed the CUS-induced decrease in sucrose
preference (p < 0.05). However, XPJY at 0.7 g/kg and
0.35 g/kg had no effect on the effect in sucrose prefer-
ence induced by CUS (p > 0.05; Table 2).
Open field exploratory behavior test
The result indicated CUS rats exhibited decreased total
ambulation, percentage of center ambulation and rearing
in comparison to control rats (p < 0.01 or p < 0.05). XPJY
1.4 g/kg and sertraline 10 mg/kg significantly reversed
the CUS-induced behavioral alterations, as observed by
increased total ambulation, percentage of central
ambulation and rearing as compared to the CUS group
(p < 0.05). XPJY 0.7 g/kg and 0.35 g/kg treatment didn’t
affect the stress induced behavior alterations in open
field test (Table 3).
Oriented navigation and spatial exploration tests
The MWM test indicated that the escape latency in the
CUS group was significantly prolonged compared to the
control group on day 1 and 2 (p < 0.01). In comparison
to the CUS group, treatment with XPJY 1.4 g/kg signifi-
cantly shortened the escape latency on day 1 (p < 0.05),
while the treatments with XPJY at 0.35 and 0.7 g/kg and
sertraline at 10 mg/kg did not show significant effect on
Table 1 Sequences of PCR primers
Gene Primes Nucleotide sequences5′-3′ Product size (bp) Accession No.
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spatial test, CUS impaired memory retrieval as indicated
by fewer crossing times of the platform position, while
sertraline 10 mg/kg and XPJY 1.4 g/Kg treatments re-
stored the CUS-induced impairment of memory retrieval
to levels seen in controls. XPJY 0.35 and 0.7 mg/kg had
no effect on the memory retrieval impairment by CUS
(p > 0.05; Table 4).Effects of XPJY on the expression of cAMP
In comparison to the control group, the expression of pro-
tein cAMP significantly decreased in the hippocampus of
the rats in CUS group (p < 0.01). The treatments with
XPJY 1.4 g/kg and sertraline 10 mg/kg significantly in-
creased the expression of protein cAMP when compared
to CUS group (p < 0.01 or p < 0.05). However, XPJY at
0.35 and 0.7 g/kg had no significant influence on the de-
crease of cAMP induced by CUS (p > 0.05; Fig. 2).Effects of XPJY on the expression of PKA, CREB and BDNF
proteins
In comparison to the control group, the expression of
protein PKA, CREB and BDNF significantly decreased in
the hippocampus of the rats in CUS group (p < 0.01).
The treatments with XPJY 1.4 g/kg and sertraline
10 mg/kg significantly increased the expression of pro-
tein PKA, CREB and BDNF when compared to CUS
group (p < 0.01). The treatments with XPJY 0.7 g/kg sig-
nificantly increased the expression of protein CREB
when compared to CUS group (p < 0.05) However, XPJY
at 0.35 and 0.7 g/kg had no significant influence on the
decrease of PKA, BDNF induced by CUS (p > 0.05).
XPJY at 0.35 had no significant influence on the decrease
of CREB induced by CUS (p > 0.05; Fig. 3).Table 2 The changes of animal body weight and sucrose preferenc
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CUS + XPJY 1.4 g/kg
CUS + XPJY 0.7 g/kg













Note: ++p < 0.01 vs Control group; **p < 0.01 vs CUS group; *p < 0.05 vs CUS groupExpression of CREB and BDNF mRNAs
The result indicated that the expression of CREB and
BDNF mRNAs was significantly decreased by CUS
when compared to control group (p < 0.01 or p < 0.05).
Chronic treatments with XPJY prevented the reduction of
CREB and BDNF mRNA expression by CUS in a dose-
dependent manner. Treatment with XPJY 1.4 g/kg and
0.7 g/kg significantly prevented the CUS-induced reduc-
tion of CREB and BDNF mRNAs expression (p < 0.01 or
p < 0.05), however XPJY 0.35 g/kg had no effect (p > 0.05).
Similarly, sertraline 10 mg/kg treatment also markedly in-
creased the expression of BDNF mRNAs (p < 0.01; Fig. 4).
Discussion
The present study utilized broadly accepted traditional
animal models – CUS model to examine depressive be-
haviors, the spatial learning and memory capability and
the expressions of mRNAs/proteins of the cAMP-PKA-
CREB-BDNF signaling. The results indicated that the
body weight gain, sucrose preference, total ambulation,
percentage of central ambulation and rearing after CUS
for 21 were significantly decreased. It indicates that the
depression model was successfully established. Then the
spatial cognitive performance in the Morris water maze
task was also decreased, which demonstrated that de-
pression by CUS had a dramatic influence on spatial
cognitive performance in the MWN test, while the treat-
ment of the rats with XPJY significantly reversed these
changes. Furthermore, the expressions of mRNAs/pro-
teins in the cascade of cAMP-PKA-CREB-BDNF signal-
ing were decreased by CUS, too. The administration of
XPJY to stressed rats prevented such metabolite reduc-
tions. These results suggest that XPJY could improve de-
pression and related learning/memory impairment
through the cAMP-PKA-CREB-BDNF signal cascade.e in different groups
Sucrose preference (%)



















Table 3 The effects of XPJY on open field test in different groups
Groups Total ambulation Central ambulation (%) Rearing
Control
CUS
CUS + sertraline 10 mg/kg
CUS + XPJY 1.4 g/kg
CUS + XPJY 0.7 g/kg



















Note: ++p < 0.01 vs Control group; +p < 0.05 vs Control group; *p < 0.05 vs CUS group
Wang et al. BMC Complementary and Alternative Medicine  (2017) 17:73 Page 6 of 12Depression is a highly debilitating and widely distributed
mental illness in the general population with a lifetime in-
cidence of 15-25%, ranking it as one of the most burden-
some diseases of society [5–7], besides enormous personal
suffering and increased mortality risk [28]. Depression
may display many different syndromes like a pervasive
low mood and loss of pleasure or interest in usual activ-
ities [1]. The patients also demonstrate sleeplessness, de-
creased body-weight [3, 4], and obvious cognitive function
impairments, such as learning and memory impairment,
etc. [5–7]. Cognitive function related to depression has re-
ceived far more attention. A growing body of research
suggests that depressive symptoms and cognitive impair-
ment are common often coexist in an individual patient,
especially in older adults. And late-life depression even is
a risk factor for cognitive decline [10]. Another clinical re-
search also found that depressed participants, in the
normal aging older adults, had a lower performance com-
pared to non-depressed participants in cognitive domains,
and the depressive symptoms may have a distinct impact
on cognitive performance [29]. The studies show that
the pattern of cognitive impairment associated with
depressive symptoms involves executive dysfunction,
reduced processing speed, and deficits in episodic
memory [30–32], while global intellectual ability, lan-
guage skills, visuospatial abilities, and semantic pro-
cessing are usually spared [33].
Among them, learning and memory impairment is one
of the important cognitive impairments and residual
symptoms, which has a strong impact on function of pa-
tients both at home and workplace, and the life quality of
patients. Many studies also have reported learning and
memory deficits in depressed subjects [3]. Further, it is be-
coming increasingly clear that the disturbance of cognitive
processes, especially the impairment of learning andTable 4 The effects of XPJY and sertraline on escapes latency in diff
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CUS + XPJY 1.4 g/kg
CUS + XPJY 0.7 g/kg













Note: ++p < 0.01 vs Control group, +p < 0.05 vs Control group; *p < 0.05 vs CUS gromemory, plays an important role in the development and
complete recurrence of depression [8, 9]. In addition, cog-
nitive impairment is also one of the typical features of re-
current depressive disorder, predominantly connected
with episodic memory processes and working memory
[11–13]. And cognitive impairment, linked with the earlier
onset of depressive symptoms and episode prolongation,
may in return lead to an ineffective antidepressant therapy
and impede full recovery [14].
In this study, the chronic unpredictable stress for
21 days was used to establish depression model of rat
and simulate the long-term negative modes and life
events of humans. The chronic unpredictable stress pro-
cedure is one of the well-validated animal models of de-
pression [34], that has good face validity in rodents as it
can elicit depression like symptoms such as lack of su-
crose preference [35, 36] interpreted as anhedonia [37]
and reduced locomotor activity [38]. Anhedonia-like be-
havior is the core symptom of human depression [39],
which means inability to experience pleasure. Anhedonia
has been defined as decreased responsiveness to rewards
[40, 41], and it is measured originally by declining intake
of a palatable sweet solution. In this experimental condi-
tions, there has been a significantly reduction of sucrose
preference in CUS group compared with the control,
which was reduced to approximately 27% at day 21 after
the beginning of stress exposure. Reduced locomotor ac-
tivity of rats in open field test may mimic some aspects
of human psychomotor retardation [42], which is an ac-
companying symptom of depression in humans [40]. In
the experimental conditions, chronic unpredictable
stress rats also exhibited depressive behavior which is
displayed by decreased total ambulation, central ambula-
tion, rearing in comparison to control rats. Depression
may also display many other different syndromes likeerent groups





















Fig. 2 Effect of XPJY on cAMP following 21 days of chronic
unpredictable stress. cAMP was reduced in the chronic
unpredictable stress group compared with control group (P < 0.01).
Chronic treatment with XPJY 1.4 g/kg significantly increase in cAMP
compared with the CUS group (P < 0.01). Sertraline 10 mg/kg group
also significantly increase in cAMP compared with the CUS group
(P < 0.05). XPJY 0.7 g/kg and 0.7 g/kg treatment did not alter stress-
induced cAMP alterations. ++P < 0.01, as compared to the control
group; *P < 0.05, as compared to the chronic unpredictable
stress group
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ory [44].
The Morris water maze has been widely used all over
the world to detecting spatial learning memory capabil-
ity [45], to objectively reflect their cognitive levels. The
rats are trained to learn to use the relationship between
environmental labels and latent platforms in order to
judge the positions of the platforms in the water. They
may thus form stable spatial cognition. The rats were
allowed to swim from the original position to the latent
platform under water by utilizing the indications at the
distal end. Their spatial learning was evaluated by re-
peated training. When the platforms under water were
withdrawn, the reference memory of the animals was de-
termined by using the frequency of penetration of the
platform position [7]. The present study found that the
escape latency in the XPJY 1.4 g/kg group on the first
day was significantly shortened, but the difference for
the sertraline group was not statistically significant. This
results shows XPJY could increase the ability of spatial
learning of depression rats by CUS. In contrast, the fre-
quency for penetrating the central areas increased both
in the XPJY 1.4 g/kg group and in the sertraline group
in the spatial exploration test on the fifth day. It indi-
cated that they can both achieve improvement with re-
gard to rats’ memory capability, while the efficacy of the
XPJY 1.4 g/kg group was more significant. This results
shows XPJY increased the ability of spatial learning
memory better than sertraline.
Previous studies have shown that chronic stressful life
events are major reactions for inducing depression and a
decrease in learning memory capability [44], as the
major target for stress. The experimental results are
Fig. 3 Effect of XPJY on hippocampal PKA, CREB and BDNF protein
level following 21 days of chronic unpredictable stress. Relative optical
density (OD) of PKA/CREB/BDNF to β-actin. PKA, CREB and BDNF were
reduced in the chronic unpredictable stress group compared with
control group (P < 0.01). Chronic treatment with XPJY 1.4 g/kg
significantly increase in PKA, CREB and BDNF compared with the CUS
group (P < 0.01). Sertraline 10 mg/kg group also significantly increase
in PKA, CREB and BDNF compared with the CUS group (P < 0.01). XPJY
0.7 g/kg group also significantly increase in PKA, CREB and BDNF
compared with the CUS group (P < 0.05). XPJY 0.7 g/kg and 0.35 g/kg
treatment did not alter stress-induced PKA, BDNF alterations (P > 0.05).
++P < 0.01, as compared to the control group; *P < 0.05, as compared
to the chronic unpredictable stress group. Representative immunoblots
of PKA/CREB/BDNF and β-actin. 1, control; 2, chronic unpredictable
stress; 3, chronic unpredictable stress plus chronic sertraline (10 mg/kg);
4, chronic unpredictable stress plus chronic XPJY (1.4 g/kg); 5, chronic
unpredictable stress plus chronic XPJY (0.7 g/kg); 6, chronic unpredictable
stress plus chronic XPJY (0.35 g/kg)
Fig. 4 CREB and BDNF mRNA expression following 21 days of
chronic unpredictable stress. 1, control; 2, chronic unpredictable
stress; 3, chronic unpredictable stress plus chronic XPJY (0.35 g/kg);4,
chronic unpredictable stress plus chronic XPJY (0.7 g/kg); 5, chronic
unpredictable stress plus chronic XPJY (1.4 g/kg); 6, chronic
unpredictable stress plus chronic sertraline (10 mg/kg). CREB and
BDNF mRNA were reduced in the chronic unpredictable stress
group compared with control group (P < 0.01). Chronic treatment
with XPJY 1.4 g/kg significantly increase in CREB and BDNF mRNA
compared with the CUS group (P < 0.01). Sertraline 10 mg/kg group
also significantly increase in cAMP compared with the CUS group
(P < 0.01). Chronic treatment with XPJY 0.7 g/kg significantly increase
in CREB and BDNF mRNA compared with the CUS group (P < 0.01 or
P < 0.05). XPJY 0.35 g/kg treatment did not alter stress-induced
CREB and BDNF mRNA alterations. ++P < 0.01, as compared to the
control group; *P < 0.05, **P < 0.01, as compared to the chronic
unpredictable stress group
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the present study show that CUS causes cognitive de-
cline and depression like symptoms whereas XPJY
showed ameliorating potential against detrimental effect
of CUS. These results are in agreement with several
other studies which also showed that UCMS causes cog-
nitive decline and depression like behavior in animal
models [38, 46].
The neurobiological mechanisms connecting the de-
pressive symptoms with cognitive and functional per-
formance are heterogeneous and have not been
completely elucidated. A number of studies have shown
that abnormalities in the hippocampus are closely asso-
ciated with the occurrence and development of depres-
sion [47–50]. Depression may affect learning memory
capability by injuring hippocampus neurons [51], which
has strong connections with depression and learning
memory capability [52]. The mechanisms for cognitive
disorder in depression mainly have two dimensions:
neurobiological and vascular factors, which may mediate
the cognitive and functional changes associated with de-
pression [53], including changes in monoamine systems
dysfunction, hormonal and immunologic changes, in-
flammatory processes, and alterations on genes expres-
sion [54]. Such as, the hypothalamic-pituitary-adrenal
axis dysfunction in depression, which relates to hippo-
campal atrophy, may be a neurobiological causal factor
to the episodic memory impairment in depressed sub-
jects [54, 55]; and white matter lesions as vascular bur-
den have be found in depressed subjects [56]. Our
earlier studies have shown that learning and memory
ability in depression rats might be related to reduce the
inflammatory factors level, such as IL-1β, IL-6 and TNF-
α, in serum and hippocampus [57].
Pathophysiological studies on depression have recently
been gradually transferred to the intracellular secondary
messenger system. As an intracellular secondary messenger,
Wang et al. BMC Complementary and Alternative Medicine  (2017) 17:73 Page 9 of 12cAMP can promote neuronal differentiation and survival
[58, 59] as well as outgrowth, regeneration [60–62] and
guidance of neuronal processes [63, 64], whose signaling
has been shown to be implicated in mechanism of reduced
synaptic plasticity, that may contribute to the pathophysi-
ology of depression [65, 66]. cAMP can activate cAMP-
dependent protein kinase (PKA), and subsequently PKA is
able to activate CREB directly by phosphorylation of the
transcription factor CREB [67] or indirectly [58, 68], thus
further mediating multiple signaling molecules, like CREB
and BDNF which play important roles in the signaling
pathway of learning memory and depression [10].
CREB is a kind of regulatory factor in nuclei, as an im-
portant component of multiple intracellular signaling
pathways in the nervous system, and is capable of regu-
lating transcription by autophosphorylation. Many intra-
cellular signal transduction cascades can influence,
directly or indirectly, the activation of CREB. Some of
the enzymes that participate in these cascades are PKA,
protein kinase C (PKC), Ca2+/calmodulindependent
protein kinase (CAMKII), extracellular-regulated protein
kinase (ERK), phosphoinositide 3-kinase (PI3K), and
glycogen synthase kinase 3 (GSK-3) [69, 70]. The down-
stream actions of CREB include the influences on
neuron synaptic plasticity and the formation of long
term memory [71, 72]. CREB is critical for the formation
of hippocampally-dependent long-term memory [73]. In
addition, CREB also decreases in the brains of patients
with depression, which are elevated in those patients
who have been using antidepressants [74].
BDNF is one of the downstream target genes of CREB,
which is the most prevalent neurotrophic factor in the
brain. It can be induced by the phosphorylation of CREB
and responsible for neuronal survival, maintenance and
growth. Some studies show that a decreased expression
of BDNF, a key target implicated both in the etiology of
depression [75], appears to be associated with depression
symptoms both in animals and humans. Depressive pa-
tients have a decrease in serum, plasma and hippocam-
pal BDNF levels in depressive patients [76, 77]. And a
decreased serum BDNF level may be an indicator of vul-
nerability to develop depression [78]. On the other hand,
several animal models of depression have also shown a
reduced expression of BDNF in brain regions [79–82]
and produce an antidepressant-like behavior [83]. Fur-
thermore, BDNF plays important roles in facilitating
both early and late phase of LTP [84, 85].
Then, CREB can induce the expression of BDNF in
general [86, 87], while BDNF can also activate the pro-
duction of CREB [11]. They form a positive feedback
ring. BDNF is the best studied neurotrophic factor im-
plicated in depression, which is also concerned to neuro-
plasticity and memory. Previous studies have found that
the expression level of BDNF in the hippocampus ofCUS induced mice markedly reduced [88]. BDNF also
could adjust the plasticity of neurons, such as plasticity
of 5-HT neurons in the central nervous system [89, 90].
It has also been indicated that the intracellular cAMP-
PKA-CREB-BDNF signaling pathway can be activated
after anti-depression therapy for a period. [11]. Previous
studies have revealed that the cAMP-PKA-CREB -BDNF
signaling is involved in depressive behaviors in animals
[18, 19, 91]. Consistently, the present study showed XPJY
prevented the reduction of the cAMP-PKA-CREB -BDNF
signaling cascade induced by CUS while improving the
depressive behaviors. The most important, the present re-
sults show the cAMP-PKA-CREB -BDNF signaling may
be also involved in the ability of spatial learning memory
of depressive rats. The ability of spatial cognitive recov-
ered with the increasement of cAMP-PKA-CREB -BDNF
signaling, suggesting the effects of XPJY may be through
regulation of the signaling pathway. Some recent studies
also supported that the ability of learning and memory im-
proved through cAMP-PKA-CREB-BDNF signaling path-
way [12, 92]. Interestingly, sertraline in the present study
showed the effect of antidepression and increasement of
signaling pathway as same as XPJY, but didn’t in spatial
learning memory test. The XPJY 1.4 g/kg group was more
advantageous than sertraline in improving the learning
memory ethology of depression rats. There are two prob-
abilities: sertraline may need more time to work, or XPJY
also work though other signaling pathway about learning
and memory. These studies indicated that XPJY plays an-
tidepression and anti learning memory impairment effect
through the cAMP-PKA-CREB -BDNF signaling pathway,
which remains to be further studied using specific
blockers of the signal pathway. Other mechanisms may
also be involved, and this still requires further study.
Recently, TCM received more and more attention in
treating depression and related syndromes [15–17].
XPJY is a common prescription in clinical practices and
shows relatively satisfactory therapeutic effect in improv-
ing depression and cognitive dysfunction. In our previ-
ous studies, we established the depression model in the
same way, and the expression of serum 5-HT and cor-
ticosterone were examined with Elisa. The results dem-
onstrated that rats subjected to CUS exhibited decreases
in serum 5-HT and increases in serum corticosterone.
The results have shown that XPJY reversed the
depression-like behaviors, increased serum 5-HT and de-
creased serum corticosterone induced by CUS in rats as
the same as sertraline could [93]. In summary, the
present study indicated that XPJY could improve the de-
pression and related syndromes in rat CUS model
through cAMP-PKA-CREB-BDNF pathway. These find-
ings are important for understanding therapeutic effects
of Chinese medicine XPJY on the impairment of learn-
ing and memory in depression.
Wang et al. BMC Complementary and Alternative Medicine  (2017) 17:73 Page 10 of 12Conclusions
XPJY has regulatory effect on depressive behavior in the
sucrose preference and open field exploration, and learn-
ing and memory in Morris water maze, and the expres-
sion of cAMP, PKA, CREB and BDNF in hippocampus
of model rats. The effect is probably achieved mainly by
activating cAMP-PKA-CREB-BDNF signaling pathway.
This study provides experimental evidence for the clin-
ical application of XPJY in the treatment of depression
and related learning and memory impairment.
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